Citadel Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.55M | Sell |
131,199
-54,220
| -29% | -$1.82M | ﹤0.01% | 4935 |
|
|
2025
Q4 | $7.94M | Buy |
185,419
+98,955
| +114% | +$3.73M | ﹤0.01% | 3568 |
|
|
2025
Q3 | $2.45M | Buy |
+86,464
| New | +$2.59M | ﹤0.01% | 5658 |
|
|
2025
Q1 | – | Sell |
-28,411
| Closed | -$576K | – | 15404 |
|
|
2024
Q4 | $478K | Buy |
+28,411
| New | +$545K | ﹤0.01% | 8655 |
|
|
2024
Q3 | – | Sell |
-16,208
| Closed | -$191K | – | 15077 |
|
|
2024
Q2 | $133K | Sell |
16,208
-27,166
| -63% | -$284K | ﹤0.01% | 10517 |
|
|
2024
Q1 | $642K | Buy |
43,374
+40,877
| +1,637% | +$551K | ﹤0.01% | 7835 |
|
|
2023
Q4 | $36.2K | Buy |
2,497
+2,280
| +1,051% | +$23.3K | ﹤0.01% | 12099 |
|
|
2023
Q3 | $2.34K | Buy |
217
+15
| +7% | +$180 | ﹤0.01% | 13736 |
|
|
2023
Q2 | $2.61K | Sell |
202
-5,232
| -96% | -$70.7K | ﹤0.01% | 13763 |
|
|
2023
Q1 | $71.7K | Sell |
5,434
-171,366
| -97% | -$2.72M | ﹤0.01% | 11697 |
|
|
2022
Q4 | $2.65M | Sell |
176,800
-281,535
| -61% | -$2.58M | ﹤0.01% | 4960 |
|
|
2022
Q3 | $5.41M | Buy |
458,335
+68,587
| +18% | +$928K | ﹤0.01% | 3738 |
|
|
2022
Q2 | $4.4M | Sell |
389,748
-7,053
| -2% | -$142K | ﹤0.01% | 4049 |
|
|
2022
Q1 | $11.9M | Buy |
396,801
+255,229
| +180% | +$6.91M | ﹤0.01% | 2699 |
|
|
2021
Q4 | $3.75M | Buy |
141,572
+127,620
| +915% | +$3.85M | ﹤0.01% | 4881 |
|
|
2021
Q3 | $506K | Buy |
13,952
+6,502
| +87% | +$256K | ﹤0.01% | 9830 |
|
|
2021
Q2 | $323K | Sell |
7,450
-322,159
| -98% | -$12.2M | ﹤0.01% | 11091 |
|
|
2021
Q1 | $11.3M | Sell |
329,609
-304,372
| -48% | -$12.1M | ﹤0.01% | 2800 |
|
|
2020
Q4 | $22.2M | Buy |
633,981
+7,905
| +1% | +$229K | 0.01% | 1692 |
|
|
2020
Q3 | $15M | Buy |
626,076
+167,396
| +36% | +$4.11M | ﹤0.01% | 1828 |
|
|
2020
Q2 | $8.39M | Buy |
458,680
+67,587
| +17% | +$1.22M | ﹤0.01% | 2431 |
|
|
2020
Q1 | $6.1M | Buy |
391,093
+19,416
| +5% | +$413K | ﹤0.01% | 2466 |
|
|
2019
Q4 | $7.95M | Sell |
371,677
-4,383
| -1% | -$90.2K | ﹤0.01% | 2477 |
|
|
2019
Q3 | $7.03M | Sell |
376,060
-62,448
| -14% | -$1.29M | ﹤0.01% | 2661 |
|
|
2019
Q2 | $11.4M | Buy |
438,508
+30,880
| +8% | +$697K | 0.01% | 2020 |
|
|
2019
Q1 | $10.5M | Sell |
407,628
-284,872
| -41% | -$6.51M | 0.01% | 2009 |
|
|
2018
Q4 | $15.9M | Buy |
692,500
+138,584
| +25% | +$3.91M | 0.01% | 1417 |
|
|
2018
Q3 | $17.8M | Sell |
553,916
-62,864
| -10% | -$1.89M | 0.01% | 1498 |
|
|
2018
Q2 | $17.5M | Buy |
616,780
+301,434
| +96% | +$10.7M | 0.01% | 1419 |
|
|
2018
Q1 | $11.2M | Sell |
315,346
-91,608
| -23% | -$3.67M | 0.01% | 1612 |
|
|
2017
Q4 | $15.8M | Buy |
406,954
+387,140
| +1,954% | +$14.7M | 0.01% | 1331 |
|
|
2017
Q3 | $503K | Buy |
19,814
+8,507
| +75% | +$207K | ﹤0.01% | 5313 |
|
|
2017
Q2 | $309K | Sell |
11,307
-5,702
| -34% | -$156K | ﹤0.01% | 5860 |
|
|
2017
Q1 | $563K | Sell |
17,009
-287,274
| -94% | -$7.32M | ﹤0.01% | 4820 |
|
|
2016
Q4 | $7.24M | Sell |
304,283
-46,153
| -13% | -$1.32M | 0.01% | 1634 |
|
|
2016
Q3 | $12.9M | Buy |
350,436
+239,325
| +215% | +$6.86M | 0.01% | 1152 |
|
|
2016
Q2 | $2.48M | Sell |
111,111
-6,037
| -5% | -$150K | ﹤0.01% | 2510 |
|
|
2016
Q1 | $2.44M | Buy |
117,148
+105,076
| +870% | +$2.59M | ﹤0.01% | 2448 |
|
|
2015
Q4 | $366K | Buy |
12,072
+987
| +9% | +$29.9K | ﹤0.01% | 4920 |
|
|
2015
Q3 | $274K | Buy |
11,085
+7,358
| +197% | +$220K | ﹤0.01% | 5702 |
|
|
2015
Q2 | $120K | Sell |
3,727
-6,264
| -63% | -$239K | ﹤0.01% | 6901 |
|
|
2015
Q1 | $356K | Buy |
+9,991
| New | +$274K | ﹤0.01% | 5414 |
|
|
2014
Q4 | – | Sell |
-1,716
| Closed | -$33K | – | 8693 |
|
|
2014
Q3 | $33K | Sell |
1,716
-5,261
| -75% | -$149K | ﹤0.01% | 7161 |
|
|
2014
Q2 | $253K | Sell |
6,977
-1,789
| -20% | -$60.8K | ﹤0.01% | 5284 |
|
|
2014
Q1 | $340K | Buy |
8,766
+7,966
| +996% | +$284K | ﹤0.01% | 4870 |
|
|
2013
Q4 | $23K | Sell |
800
-971
| -55% | -$28.5K | ﹤0.01% | 6391 |
|
|
2013
Q3 | $63K | Sell |
1,771
-3,013
| -63% | -$110K | ﹤0.01% | 5653 |
|
|
2013
Q2 | $160K | Buy |
+4,784
| New | +$217K | ﹤0.01% | 4855 |
|
Other funds holding RIGL
AC
VCM
Citadel Advisors's RIGL Position: Q1 2026 in Review
Citadel Advisors reduced its Rigel Pharmaceuticals (RIGL) stake by 29% in Q1 2026, selling an estimated $1.82M and leaving 131,199 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #4935.
Citadel Advisors first reported a position in RIGL in Q2 2013 and has held it in 48 quarters since. The position peaked at $22.2M in Q4 2020. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Citadel Advisors held 131,199 shares of Rigel Pharmaceuticals worth $3.55M as of Q1 2026.
- Citadel Advisors sold 54,220 Rigel Pharmaceuticals shares in Q1 2026, an estimated $1.82M.
- Rigel Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4935 holding.
- Citadel Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
- Citadel Advisors's Rigel Pharmaceuticals position peaked at $22.2M in Q4 2020.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.